go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

North Dakota rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $489,779 · 10th–90th $489,779$870,9640%50%90th$489,779Professionalmedian $489,779 · 10th–90th $489,779$741,3100%50%90th$489,779$500.0K$1.0M$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$870,963.59
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
Cigna
Setting
Professional
Modifier
Global
Typical Low
$457,088.19
Median
$467,735.14
Typical High
$588,843.66
Medica
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$758,577.58
Typical High
$1,548,816.62
Medica
Setting
Professional
Modifier
Global
Typical Low
$1,000,000.00
Median
$1,000,000.00
Typical High
$1,000,000.00
United
Setting
Facility
Modifier
Global
Typical Low
$537,031.80
Median
$537,031.80
Typical High
$537,031.80
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$436,515.83
Typical High
$741,310.24